BCL2 and myelodysplastic syndrome: Although primary mice died of MDS/MPNs between 6–10 weeks post-injection of active MEK+ or Bcl-2/active MEK+ HSCs, secondary mice transplanted with Bcl-2/active MEK+ MDS/MPNs did not became sick until at least 15 weeks post-injection (Figure 4A).